News
Vinay Prasad is returning to his role at the U.S. Food and Drug Administration, a little more than a week after he had left ...
2hon MSN
Vinay Prasad is returning to his role at the U.S. Food and Drug Administration to resume overseeing vaccine, gene therapy and ...
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...
Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...
WASHINGTON — Vinay Prasad is returning to the Food and Drug Administration to resume his role overseeing vaccine, gene ...
20h
Medpage Today on MSNFDA Restricts Gene Therapy Skysona Due to Blood Cancer RiskThe FDA approved labeling changes for elivaldogene autotemcel (eli-cel; Skysona), a one-time gene therapy for patients with early, active cerebral adrenoleukodystrophy (CALD), to reflect new safety ...
Vinay Prasad, who was recently ousted as the top vaccine and gene therapy regulator at the US Food and Drug Administration, is returning to his role, the Department of Health and Human Services said ...
Once dismissed as “junk” DNA, ancient viruses embedded in the human genome play a key role in early human development, ...
Net loss (GAAP) widened to $2.6 million, driven by increased expenses from the GPCR Therapeutics USA Inc. acquisition. Management issued a going concern warning, citing $7.9 million in cash and cash ...
Carmen Keogh, 33, believed she was in perfect health when a routine check-up identified her body was riddled with tumours.
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune cle ...
A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results